The TAGGS Assistance Listing Report provides detailed award information for a single Assistance Listing. The data provided is from FY 2008 or from the start date of data collection through the present. For information prior to FY 2008, please use the TAGGS Advanced Search.
In the top display you will see the name of the Assistance Listing, agency, assistance type, and any popular name it might use, along with the 5-digit CFDA number.
Assistance Listings consisting of Direct Payment Awards may not contain links to additional recipient and award information. Direct Payment data is often collected as aggregated payments to a state to protect the personal information of the assistance recipients.
Along with the bar chart broken up by Issue Date or Funding Fiscal Year, there is also an exportable table below that groups by Issue Date or Funding Fiscal Year and shows the recipient name, state, award number, award title and amount from each award action.
By using the radio buttons, you may view data by the Issue Date Fiscal Year of by Funding Fiscal Year. In most cases, the Issue Date and Funding Fiscal Years coincide, although in some cases, delays in issuing an award and award close outs will cause the Issue Date of an award to be outside the of the Funding Fiscal Year.
Table data can be exported by choosing one of the export-format icons located at the top right of the table. Export file formats include:
The two Fiscal Year (FY) viewing options are:
|Issue Date FY||The FY in which the award action Occurred|
|Funding FY||The FY in which the award action Funded|
To enter Keyboard Support and Web Page Reader Support for the report results grid view, you will need to press Ctrl Shift G
|Move through rows||← ↑ ↓ →|
|Next page||SHIFT PAGE DOWN|
|Previous page||SHIFT PAGE UP|
|Move through column headers and data fields||TAB|
|Sort ASC/DESC when a column header is selected||ENTER|
Objectives: The purpose of this program is to coordinate the acceleration of countermeasure and product advanced research and development byâ€”(A) facilitating collaboration between the Department of Health and Human Services and other Federal agencies, relevant industries, academia, and other persons, with respect to such advanced research and development; (B) promoting countermeasure and product advanced research and development; (C) facilitating contacts between interested persons and the offices or employees authorized by the Secretary to advise such persons regarding requirements under the Federal Food, Drug, and Cosmetic Act and under section 351 of the Public Health Service Act; and (D) promoting innovation to reduce the time and cost of countermeasure and product advanced research and development. The Public Health Service Act at 42 U.S.C. 247d-6a defines a qualified countermeasure as â€œâ€¦a drug (as that term is defined by section 321(g)(1) of title 21), biological product (as that term is defined by section 262(i) of this title), or device (as that term is defined by section 321(h) of title 21), that the Secretary determines to be a priority (consistent with sections 182(2) and 184(a) of title 6) to - (i) diagnose, mitigate, prevent, or treat harm from any biological agent (including organisms that cause an infectious disease) or toxin, chemical, radiological, or nuclear agent that may cause a public health emergency affecting national security; or (ii) diagnose, mitigate, prevent, or treat harm from a condition that may result in adverse health consequences or death and may be caused by administering a drug, biological product, or device that is used as described in this subparagraphâ€¿